Daiichi Sankyo Company (D4S0) Resumen de Acciones

Daiichi Sankyo Company, Limited fabrica y vende productos farmacéuticos en Japón, Norteamérica, Europa e internacionalmente. Saber más

Análisis fundamental de D4S0
Puntuación del snowflake
Valoración	4/6
Crecimiento futuro	2/6
Rendimiento pasado	1/6
Salud financiera	5/6
Dividendos	4/6

Recompensas

Cotiza un 40.8% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 12.03%

Análisis de riesgos

Alto nivel de ganancias no monetarias

El dividendo de 3.39% no está bien cubierto por los flujos de efectivo libres

D4S0 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW427,787 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

427,787 investors already sharing narratives

View all narratives

Competidores de Daiichi Sankyo Company, Limited

Historial de precios y rendimiento

Resumen de las cotizaciones máximas, mínimas y variaciones del Daiichi Sankyo Company
Precios históricos de las acciones
Precio actual de la acción	JP¥15.60
Máximo en las últimas 52 semanas	JP¥23.40
Mínimo de 52 semanas	JP¥12.30
Beta	-0.16
Cambio en 1 mes	13.04%
Variación en 3 meses	11.43%
Cambio de 1 año	-25.00%
Variación en 3 años	n/a
Variación en 5 años	n/a
Variación desde la OPV	-40.91%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	D4S0	DE Pharmaceuticals	Mercado DE
7D	9.1%	-0.7%	-1.1%
1Y	-25.0%	38.6%	3.3%

Rentabilidad vs. Industria: Los resultados de D4S0 fueron inferiores a los de la industria German Pharmaceuticals, que obtuvo un rendimiento del 38.6% el año pasado.

Rentabilidad vs. Mercado: D4S0 obtuvo unos resultados inferiores a los del mercado German, que fueron del 3.3% el año pasado.

Volatilidad de los precios

Is D4S0's price volatile compared to industry and market?
D4S0 volatility
D4S0 Average Weekly Movement	6.6%
Pharmaceuticals Industry Average Movement	4.8%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	12.0%
10% least volatile stocks in DE Market	2.5%

Precio estable de las acciones: D4S0 no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado German.

Volatilidad a lo largo del tiempo: La volatilidad semanal de D4S0 (7%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1899	20,171	Hiroyuki Okuzawa	www.daiichisankyo.com

Daiichi Sankyo Company, Limited fabrica y vende productos farmacéuticos en Japón, Norteamérica, Europa e internacionalmente. La empresa ofrece Enhertu para tratar a pacientes con cáncer de mama HER2 positivo y bajo, adenocarcinoma gástrico o de la unión gastroesofágica HER2 positivo y tumores sólidos HER2 positivos; Turalio, una pequeña molécula oral dirigida contra el receptor del factor estimulante de colonias 1, la tirosina cinasa del receptor protooncogénico KIT y la tirosina cinasa 3 similar a FMS que alberga una mutación de duplicación interna en tándem; Vanflyta, un inhibidor de FLT3 para el tratamiento de pacientes adultos con leucemia mieloide aguda; e Injectafer, una inyección de carboximaltosa férrica para tratar la deficiencia de hierro. También ofrece Liziana y Savaysa, inhibidores directos del factor Xa; Minnebro, Olmetec, Olmetec Plus, Rezaltas, Sevikar y Sevikar HCT, agentes antihipertensivos; Nilemdo, un tratamiento oral que reduce el colesterol; Nustendi, un comprimido combinado de dosis fija de ácido bempedoico y ezetimiba para reducir el colesterol; y Efient, un agente antiagregante plaquetario.

Resumen de fundamentos de Daiichi Sankyo Company, Limited

¿Cómo se comparan los beneficios e ingresos de Daiichi Sankyo Company con su capitalización de mercado?
Estadísticas fundamentales de D4S0
Capitalización bursátil	€29.86b
Beneficios(TTM)	€1.46b
Ingresos (TTM)	€12.35b

20.5x

Ratio precio-beneficio (PE)

2.4x

Ratio precio-ventas (PS)

¿Está D4S0 sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de D4S0
Ingresos	JP¥2.22t
Coste de los ingresos	JP¥700.99b
Beneficio bruto	JP¥1.52t
Otros gastos	JP¥1.26t
Beneficios	JP¥262.87b

Últimos beneficios comunicados

Jun 30, 2026

Próxima fecha de beneficios

Oct 30, 2026

Beneficios por acción (BPA)	144.40
Margen bruto	68.47%
Margen de beneficio neto	11.82%
Ratio deuda/patrimonio	29.4%

¿Cómo se ha desempeñado D4S0 a largo plazo?

Ver rendimiento histórico y comparativa

Dividendos

3.4%

Rentabilidad actual por dividendo

55%

Ratio de pagos

Análisis de la empresa y estado de los datos financieros

Datos	Última actualización (huso horario UTC)
Análisis de la empresa	2026/09/18 13:13
Precio de las acciones al final del día	2026/09/18 00:00
Beneficios	2026/06/30
Ingresos anuales	2026/03/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

Paquete	Datos	Marco temporal	Ejemplo Fuente EE.UU. ^*
Finanzas de la empresa	10 años	Cuenta de resultados Estado de tesorería Balance	Formulario SEC 10-K Formulario SEC 10-Q
Estimaciones del consenso de analistas	+3 años	Previsiones financieras Objetivos de precios de los analistas	Informes de análisis Blue Matrix
Precios de mercado	30 años	Precios de las acciones Dividendos, escisiones y acciones	Datos de mercado ICE Formulario S-1 de la SEC
Propiedad	10 años	Accionistas principales Información privilegiada	Formulario SEC 4 Formulario SEC 13D
Gestión	10 años	Equipo directivo Consejo de Administración	Formulario SEC 10-K Formulario SEC DEF 14A
Principales avances	10 años	Anuncios de empresas	Formulario SEC 8-K

^* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Daiichi Sankyo Company, Limited está cubierta por 28 analistas. 15 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

Analista	Institución
Atsushi Seki	Barclays
Miki Sogi	Bernstein
Koichi Mamegano	BofA Global Research

Daiichi Sankyo Company (D4S0) Resumen de Acciones

Recompensas

Análisis de riesgos

Join community and earn perks

Competidores de Daiichi Sankyo Company, Limited

Merck KGaA

Dermapharm Holding

Sartorius

Astellas Pharma

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Daiichi Sankyo Company, Limited to Report Q2, 2027 Results on Oct 30, 2026

Court Dismisses Northern TK Venture Pte Ltd Claims in Material Litigation Against Daiichi Sankyo Company, Limited

Daiichi Sankyo And AstraZeneca Receive Approval For Enhertu Plus Pertuzumab As First-Line Treatment For HER2 Positive Metastatic Breast Cancer In The EU

Daiichi Sankyo Presents New Data On Bempedoic Acid In Real-World Management Of Dyslipidemia And Cardiovascular Risk

Daiichi Sankyo and Astrazeneca Initiate Tropion-Urothelial04 Phase 3 Trial of Datroway as Adjuvant Therapy in High-Risk Muscle Invasive Urothelial Cancer

Daiichi Sankyo Co., Ltd. Announces Executive Changes

Recent updates

Daiichi Sankyo Company, Limited to Report Q2, 2027 Results on Oct 30, 2026

Court Dismisses Northern TK Venture Pte Ltd Claims in Material Litigation Against Daiichi Sankyo Company, Limited

Daiichi Sankyo And AstraZeneca Receive Approval For Enhertu Plus Pertuzumab As First-Line Treatment For HER2 Positive Metastatic Breast Cancer In The EU

Daiichi Sankyo Presents New Data On Bempedoic Acid In Real-World Management Of Dyslipidemia And Cardiovascular Risk

Daiichi Sankyo and Astrazeneca Initiate Tropion-Urothelial04 Phase 3 Trial of Datroway as Adjuvant Therapy in High-Risk Muscle Invasive Urothelial Cancer

Daiichi Sankyo Co., Ltd. Announces Executive Changes

AstraZeneca PLC And Daiichi Sankyo Co., Ltd. Report Enhertu Demonstrates Statistically Significant Improvement In Progression-Free Survival In First-Line HER2-Mutant Advanced Non-Small Cell Lung Cancer In DESTINY-Lung04 Phase III Trial

Datroway® Approved in the Eu as Only Trop2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic Tnbc Who Are Not Candidates for Immunotherapy

Datroway Recommended for Approval in EU for TNBC

Daiichi Sankyo and AstraZeneca Receive Approval for Enhertu as First Tumor Agnostic HER2 Directed Therapy in the EU

Daiichi Sankyo and AstraZeneca Announce Datroway Recommends for Approval in EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy

Daiichi Sankyo Company, Limited to Report Q1, 2027 Results on Jul 31, 2026

Daiichi Sankyo Presents New Clinical Research And Product Pipeline Updates Across Oncology Portfolio At ASCO

Daiichi Sankyo and Astrazeneca Announce Approval of Datroway as First Trop2 Directed Antibody Drug Conjugate for First-Line Treatment of Metastatic Triple Negative Breast Cancer in the U.S

Astrazeneca and Daiichi Sankyo Receive Us Approval for Enhertu for Two New Indications in Her2-Positive Early Breast Cancer

Daiichi Sankyo Company, Limited, Annual General Meeting, Jun 22, 2026

Suntory Holdings Limited signed a letter of intent to acquire Daiichi Sankyo Healthcare Co., Ltd. from Daiichi Sankyo Company, Limited (TSE:4568) for approximately ¥250 billion.

Daiichi Sankyo Company, Limited to Report Q4, 2026 Results on Apr 27, 2026

Daiichi Sankyo And AstraZeneca Announce Acceptance And Priority Review Of Supplemental Biologics License Application For ENHERTU For HER2 Positive Breast Cancer

Daiichi Sankyo Company, Limited Announces Board Retirements, Effective March 31, 2026

Daiichi Sankyo Company, Limited Announces Executive Changes, Effective April 1, 2026

European Medicines Agency Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer

Daiichi Sankyo Announces First Patient Has Been Dosed in A First-In-Human Phase 1/2 Trial

Daiichi Sankyo And AstraZeneca Receive Priority Review For DATROWAY For Treatment Of Unresectable Or Metastatic Triple Negative Breast Cancer In The U.S

National Medical Products Administration Approves Enhertu in China as the First and Only Her2 Directed Dc for the Second-Line Treatment of Patients with Her2 Positive Metastatic Gastric Cancer

Daiichi Sankyo Appoints Veronika Rozehnal, Ph.D., as Head of Translational Research Center Europe

European Medicines Agency Validated in the EU as First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer

TROPION-Lung17 TROP2 Biomarker Directed Phase 3 Trial of DATROWAY Initiated in Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer

Enhertu® Granted Breakthrough Therapy Designation in the U.S. as Post-Neoadjuvant Therapy for Patients with Her2 Positive Early Breast Cancer

Daiichi Sankyo and AstraZeneca's DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy

Astrazeneca and Daiichi Sankyo's ENHERTU®? (Fam-Trastuzumab Deruxtecan-nxki) Approves in the US as First New Treatment in A decade for the 1st-Line Treatment of Patients with HER2-Positive Metastatic Breast Cancer

Destiny-Ovarian01 Phase 3 Trial of Enhertu Initiated as First-Line Maintenance Therapy in Patients with Her2 Expressing Advanced Ovarian Cancer

Federal Circuit Court of Appeals Vacates Infringement Judgment and Damages Award in Dispute Between Daiichi Sankyo and Seagen

Daiichi Sankyo Company, Limited to Report Q3, 2026 Results on Jan 30, 2026

Daiichi Sankyo Announces Dosed in First-In-Human Phase 1 Trial Evaluating Ds3610 in Patients with Advanced Solid Tumors

DESTINY-Lung06 Phase 3 Trial of ENHERTU Initiated as First-Line Therapy in Patients with HER2 Overexpressing Metastatic Non-Small Cell Lung Cancer

Daiichi Sankyo Company, Limited Announces DS-3939 Shows Promising Preliminary Clinical Activity in Patients with Advanced Solid Tumors in Phase 1/2 Trial

Daiichi Sankyo And AstraZeneca Present Initial Results For DATROWAY Plus Rilvegostomig Combination Therapy in Urothelial Cancer

Daiichi Sankyo Continues to Transform Standards of Care for Patients with Three Landmark Breast Cancer Trials

AstraZeneca and Daiichi Sankyo Announces Positive High-Level Results from the TROPION-Breast02 Phase III Trial

Daiichi Sankyo and Astrazeneca's Supplemental Biologics License Application Accepted in the U.S. for Patients with High-Risk Her2 Positive Early-Stage Breast Cancer Prior to Surgery

Daiichi Sankyo and AstraZeneca's Supplemental Biologics License Application for Enhertu®? in Combination with Pertuzumab Deruxtecan-nxki

Daiichi Sankyo and Merck Announce Raludotatug Deruxtecan Receives Breakthrough Therapy Designation by U.S. FDA for Patients with CDH6 Expressing Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancers Previously Treated with Bevacizumab

ENHERTU® Type II Variation Application Validated in the EU for Previously Treated Patients with HER2 Positive Metastatic Solid Tumors

Ifinatamab Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in Ideate-Lung01 Phase 2 Trial

Daiichi Sankyo Company, Limited to Report Q2, 2026 Results on Oct 31, 2025

Merck's First Patient Dosed in the HERTHENA-Breast04 Phase 3 Trial of Patritumab Deruxtecan Initiated in Patients with Metastatic Hormone Receptor

Daiichi Sankyo and Merck Announce U.S. Food and Drug Administration Grants Breakthrough Therapy Designation for Patients with Pretreated Extensive-Stage Small Cell Lung Cancer

Daiichi Sankyo Presents New Data in Small Cell Lung Cancer and Updates Across Adc Portfolio Highlighting Progress in Creating New Standards of Care for Patients with Lung Cancer At Wclc

Enhertu Plus Pertuzumab Granted Breakthrough Therapy Designation in the U.S. as First-Line Therapy for Patients with Her2 Positive Metastatic Breast Cancer

Turalio Final Long-Term Data Showed Sustained Clinical Benefit in Patients with Tenosynovial Giant Cell Tumor from Open-Label Extension of Enliven Phase 3 Trial

Datroway Approves in Us for EGFRm Lung Cancer

IDeate-Prostate01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Pretreated Metastatic Castration-Resistant Prostate Cancer

Daiichi Sankyo Company, Limited to Report Q1, 2026 Results on Jul 31, 2025

DATROWAY Continues to Show Promising Tumor Responses as Part of Combination Regimens in Patients with Early and Advanced Non-Small Cell Lung Cancer

Daiichi Sankyo and Merck Announces Patritumab Deruxtecan Biologics License Application for Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer Voluntary Withdraw

IHH Healthcare Berhad Provides Update on Material Litigation by Northern TK Venture Pte Ltd Against Daiichi Sankyo Company, Limited

Daiichi Sankyo, Inc. Announces Positive Topline Results from the Destiny-Breast11 Phase 3 Trial

Daiichi Sankyo Company, Limited, Annual General Meeting, Jun 23, 2025

Enhertu Plus Pertuzumab Demonstrated Highly Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival Versus THP as First-Line Therapy for Patients with HER2 Positive Metastatic Breast Cancer

Daiichi Sankyo and AstraZeneca Announce European Union Approves DATROWAY®? for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer

Daiichi Sankyo and AstraZeneca's ENHERTU Approves in the EU as First HER2 Directed Therapy for Patients with HR Positive, HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy